Immunopathogenic Mechanisms and Immunoregulatory Therapies in MASLD

Steatosis Liver Disease Shows Increased Risk of Diabetes for Patients With Atrial Fibrillation

Investigators find that the risk for new-onset diabetes is especially prominent for patients aged 20 to 29 years.

Immunopathogenic Mechanisms and Immunoregulatory Therapies in MASLD

Scientists provide an in-depth discussion of current data related to the immunological mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) and summarize the effects of current and experimental therapies on immunoregulation in MASLD. [Cellular & Molecular Immunology] Full Article

Popular Diabetes Drug Helps Treat Progressive Liver Disease

TOPLINE: When administered for 48 weeks, the SGLT2 inhibitor dapagliflozin alleviated steatohepatitis and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) while demonstrating a favorable safety profile. METHODOLOGY: MASH affects over 5% of adults and more than 30% of patients with diabetes or obesity. It is characterized by hepatic steatosis, lobular inflammation, and hepatocellular ballooning […] The post Popula…